Table 2

Common core of transcripts significantly deregulated by bexarotene and gefitinib treatments in mammary epithelium from p53-null mice

TagGeneDescriptionFold change*BGT
Transcriptional regulation/signal transduction
 CATCTGTATTFosl2Fos-like antigen 26.0
 GGTTTTGTTTWsb1WD repeat and SOCS box-containing 16.2
 GGATATGTGGEgr1Early growth response 12.1
 GCGCCCTTCCCcl21bChemokine (C-C motif) ligand 21b−2.8
 GATTTCTGTCGng5Guanine nucleotide binding protein γ5−1.7
Cell cycle/proliferation
 AAATCCTTTCPtnPleiotrophin2.6
 TATAGTATGTGlulGlutamate-ammonia ligase1.9
 CAGCATAAATDip3bDip3β−7.2
 GCCAAACCAAClk1CDC-like kinase 1−1.9
Cytoskeleton organization/extracellular matrix remodeling
 CTCCTGGACAGsnGelsolin3.1
 TTAACTCTGAPrelpProline arginine-rich end leucine-rich repeat2.8
 CCCTGAGTCCActbActin, β, cytoplasmic2.5
 CTGAGGAAGTSparcl1SPARC-like 12.1
 ATAGCCCCAACtssCathepsin S−5.1
 TTTTATTCTCCapn12Calpain 12−6.0
 GGCTGTTGAACsrp1Cysteine and glycine-rich protein 1−1.6
Protein metabolism
 TTACCATTGCTiparpTCDD-inducible poly(ADP-ribose) polymerase2.8
 CCAGGTTATTNola3Nucleolar protein family A, member 3−6.5
 TGACCCCGGGUba52Ubiquitin A-52 residue ribosomal protein−2.3
 TGGTGTAGGAHspa5Heat shock 70-kDa protein 5−1.5
 TGGGTTGTCTTpt1Tumor protein translationally controlled 1−1.5
 GTGAAACTAARps4xRibosomal protein S4, X-linked−1.5
 CTAATAAAGCFauFinkel-Biskis-Reilly murine sarcoma virus−1.3
Miscellaneous
 TGGATCCTGAHbb-b1Hemoglobin, β adult major chain15.5
 TAAATTAAGAHexbHexosaminidase B8.5
 GAGGACTGCCLy6eLymphocyte antigen 6 complex, locus E6.2
 CCCTTCTTCTHba-a1Hemoglobin α, adult chain 13.3
 CCAGGCCTTACrip1Cysteine-rich protein 12.2
 TGCACTATTG1500012F01RIKEN cDNA 1500012F01 gene−4.4
 AACTAGAAAANdufs2NADH dehydrogenase Fe-S protein 2−4.2
 TAAGGGAAATTpi1Triosephosphate isomerase 1−2.3
 CCAAATAAAALdhaLactase dehydrogenase A−2.2
 CTAATAAAAGCox4i1Cytochrome c oxidase subunit IV isoform 1−2.1
 TAAAGCAAAAHist1h2bcHistone 1, H2bc−1.9

Abbreviations: B, bexarotene treatment; G, gefitinib treatment; T, p53-null mammary tumors.

  • *Up-regulated transcripts are represented by positive average fold changes and down-regulated transcripts are represented by negative average fold changes among bexarotene and gefitinib treatments.